SecBot SecBot
144 ·Filed Oct 30, 2026

LGND

LIGAND PHARMACEUTICALS INC
NEUTRAL
Impact 1/10
Horizonimmediate Processed17d 10h ago SEC0001949846-26-000627
Form 144: notice of proposed sale of securities
Actionable Insight • Neutral

The filing is a routine advance notice of a small insider sale by a director. No material impact is expected. Monitor for any subsequent Form 4 filings to confirm execution, but this is not a signal of insider concern.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$322.75
T+0 close · Oct 30, 2026 · via day close
Latest settled
−5.13%
T+5 · $306.20 · next T+20 in 13d
Vs SPY
−2.42%
α at T+5
Latest observation
−1.61%
T+9 · FF3 residual α
  1. T+0 · Oct 30 $322.75entry
  2. T+1 · 15d ago −4.87%α −4.39% · $307.02
  3. T+5 · 11d ago −5.13%α −2.42% · $306.20
  4. T+11 · todayOpen
  5. T+20 · in 13d Pending
  6. T+60 · in 2mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Director Jason Aryeh filed a Form 144 notice of intent to sell 202 shares of Ligand Pharmaceuticals common stock, with an estimated market value of approximately $64,738 based on the filing date. The proposed sale is small relative to the company's $6.4B market cap and the director's holdings, and the filing is a routine advance notice of a planned trade.

Key Facts

  • Director Jason Aryeh filed Form 144 on 2026-10-30 for a proposed sale of 202 shares of Ligand Pharmaceuticals common stock.
  • The estimated value of the proposed sale is $64,738.
  • The shares were acquired on 03/13/2019 via an open market purchase.
  • The proposed sale is to be executed through Charles Schwab & Co., Inc. on Nasdaq.
  • The sale represents a negligible fraction of the company's $6.4B market cap.

Financial Impact

Proposed sale of 202 shares valued at $64,738, a de minimis amount relative to the company's $6.4B market cap.

Risk Factors

  • Form 144 is only an intent to sell; the sale may not be executed.
  • No other insider selling patterns or context provided to suggest broader insider sentiment.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001949846-26-000627
Document: 0001949846-26-000627-index.html0001949846-26-000627
Document: 0001949846-26-000627.txt0001949846-26-000627

US Market Status

Market Closed · Opens in 8h 44m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 30, 2026